Wegovy injection pens organized in Waterbury, Vermont, US, on Monday, April 28, 2025.
Shelby Knowles | Bloomberg | Getty Images
Danish pharmaceutical big Novo Nordisk on Wednesday introduced plans to cut around 9,000 roles, or roughly 11% of its world workforce.
“Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources towards the company’s growth opportunities in diabetes and obesity,” the corporate, which produces the Wegovy weight reduction treatment, mentioned in a press release,
“As part of the transformation, Novo Nordisk intends to reduce the global workforce by approximately 9,000 of the 78,400 positions in the company, with around 5,000 reductions expected in Denmark.”
The firm mentioned the headcount discount would incur a one-off price of 8 billion Danish kroner ($1.26 billion).
As a results of the one-off prices, the corporate mentioned its now anticipate full-year working revenue development of 4% to 10%, down from the ten% to 16% outlined in its second-quarter ends in August.
This is a growing story and might be up to date shortly.